Work

Response to Tyrosine Kinase Inhibitors in Patients with BCR-ABL1 Positive Chronic Myeloid Leukemia; 20 Years’ Experience at Patan Hospital, Nepal

Year: 2024

Type: article

Abstract: BACKGROUNDChronic Myeloid Leukemia (CML) is characterized by the accumulation of immature white blood cells due to the Philadelphia chromosome, producing the BCR-ABL1 oncogene.Targeted therapies like Imatinib, Dasatinib, Nilotinib, and Ponatinib inhibit BCR-ABL1 activity, transforming CML into a manageable condition with favorable outcomes.Introduced in 2003 at Patan Hospital, Imatinib was followed by newer Tyrosine kinase inhibitors(TKIs) including third-generation options, addressing treatment resistance and enhancing survival rates.

Source: International Journal of Cancer Care and Delivery

DOI: 10.53876/001c.123900

Authors: Cellina Maharjan, Pragya Rai, Nabina Thapa, Gyan Krishna Kayastha

Institution: Patan Academy of Health Sciences

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4403169014